Biomedical · Investment · Legal · Publications
Investment Evidence Research
Evidence reviews of questions that matter in investment due diligence.
Not investment advice. These pages summarise published research. They do not evaluate any company, asset or security.
Articles
Human genetic evidence and the success of drug programmes in clinical development
Research question: Among drug programmes already in clinical development, how much incremental information does human genetic evidence give about the probability of success, and what are the limits of that information for biotech due diligence?
AI-assisted draft Last verified 2026-10-24 · probability of clinical success only; not valuation or return
How to read these articles
Every article uses the SYCDS Evidence Research Format (ERF): a research question, key findings, an evidence table with a check label on every claim, limitations, counterevidence, decision implications, what would change the assessment, and a dated update history.
- Abstract-checked checked against the published abstract or public record only.
- Partly verified checked through automated extraction from the full text, or through a secondary report; manual review pending.
- Inferred follows from other rows; no direct source.
- Overstated a source contradicts part of the claim.
- Interpretation a judgment, not a checkable fact.
No article is yet full-text-checked or reviewed by an independent expert. Each article states its own research status.
SYCDS Research · Articles are AI-assisted drafts unless stated otherwise · Not medical, investment or legal advice · Tac Yang